FLXN
PACIRA THERAPEUTIC INC
PACIRA THERAPEUTIC INC historical holders
total: 1
Miller Value Partners PACIRA THERAPEUTIC INC transactions over time
- Total transactions:
- 17
- New positions:
- 1
- Sold out:
- 1
- Added:
- 9
- Reduced:
- 6
- Held since:
- 2017 Q2
- Held for:
- 16 quarters
- Latest activity:
- 2021 Q2
Bill Miller has been an institutional investor in PACIRA THERAPEUTIC INC (FLXN) since 2017 Q2. According to 2026 Q1 report, Bill Miller doesn't hold any shares. The fund/company first acquired FLXN in 2017 Q2, initially purchasing 527,800 shares. Since the initial investment, Miller Value Partners has made 16 more transactions in this position.
When did Bill Miller exit their FLXN position?
Bill Miller no longer holds PACIRA THERAPEUTIC INC (FLXN). They sold off their entire position in 2021 Q2, closing out an investment that began in 2017 Q2.
When did Bill Miller first invest in FLXN?
Bill Miller first invested in PACIRA THERAPEUTIC INC (FLXN) in 2017 Q2 at the reported quarter-end price of $20.22 per share, acquiring 527,800 shares in their initial purchase.
What is Bill Miller's average cost basis for FLXN?
Based on historical transaction data, Bill Miller's estimated cost basis for PACIRA THERAPEUTIC INC (FLXN) is approximately $17.66 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $17.66
- Weighted AVG sell price:
- $9.88
FLXN transactions history by Miller Value Partners
17 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q2
|
0.00%
|
0
|
$8.95
|
|
-100% (-4,101,735)
|
-1.04%
|
|
2021 Q1
|
1.04%
|
4,101,735
|
$8.95
|
$36,711,000
|
-2.25% (-94,365)
|
-0.03%
|
|
2020 Q4
|
1.64%
|
$11.54
|
-20.44% (-1,078,339)
|
|||
|
2020 Q3
|
2.17%
|
$10.41
|
+1.52% (+78,889)
|
|||
|
2020 Q2
|
3.03%
|
$13.15
|
+22.55% (+956,081)
|
|||
|
2020 Q1
|
2.15%
|
$7.87
|
-14.06% (-693,406)
|
|||
|
2019 Q4
|
3.65%
|
$20.70
|
-5.42% (-282,935)
|
|||
|
2019 Q3
|
2.89%
|
$13.71
|
+7.49% (+363,350)
|
|||
|
2019 Q2
|
2.38%
|
$12.30
|
+18.07% (+742,740)
|
|||
|
2019 Q1
|
2.04%
|
$12.48
|
+32.00% (+996,330)
|
|||
|
2018 Q4
|
1.61%
|
$11.32
|
+8.06% (+232,190)
|
|||
|
2018 Q3
|
1.76%
|
$18.71
|
+8.57% (+227,425)
|
|||
|
2018 Q2
|
2.58%
|
$25.85
|
-0.60% (-16,125)
|
|||
|
2018 Q1
|
2.56%
|
$22.41
|
-0.54% (-14,600)
|
|||
|
2017 Q4
|
2.91%
|
$25.04
|
+127.24% (+1,503,175)
|
|||
|
2017 Q3
|
1.31%
|
$24.18
|
+123.82% (+653,525)
|
|||
|
2017 Q2
|
0.49%
|
$20.22
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.